Navigation Links
Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
Date:1/30/2008

BONITA SPRINGS, Fla., Jan. 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, has initiated a multi-center, Phase I, ascending dose clinical study of aminoflavone pro-drug (AFP-464) for the treatment of cancer. The first patient was dosed in December 2007 and enrollment is ongoing.

The primary objectives of the study are to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of AFP-464 in patients with advanced solid tumors. The trial is expected to enroll up to approximately 35 patients across two sites in Europe: Institut Gustave-Roussy, Villejuif, France and Jules Bordet Institute, Brussels, Belgium. Results from the trial are expected to be available in early 2009.

"We are delighted that dosing has begun in this important dose-escalation study of AFP-464 in patients with solid tumors," said Edmundo Muniz, Chief Executive Officer of Tigris. "AFP-464 is a first-in-class molecule with the potential to fill a large unmet medical need in the treatment of cancer. This first trial in Europe along with the two US Phase 1 trials provides us our first opportunity to assess the drug's activity in patients, and to further build on our understanding of the molecule's mechanism of action."

About AFP-464

AFP-464 is a novel anticancer agent currently being investigated in two phase 1 clinical trials sponsored by the National Cancer Institute ("NCI") in patients with solid tumors. Preclinical studies into AFP-464's mechanism of action have shown that AFP-464 is converted to metabolites which bind covalently to DNA, resulting in p53 activation and apoptosis. AFP-464 has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor cell line screen, with breast, ovarian, lung and renal tumor cell lines exhibiting particular sensitivity to the compound. In vivo antitumor activity of AFP-464 has been demonstrated in several xenograft studies in mice bearing renal and brea
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
2. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
3. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
8. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
9. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
10. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 BiondVax ... preliminary results from its BVX-006 Phase II clinical trial ... In this trial, M-001 was injected intramuscularly to volunteers ... an administration of the 2014/15 season trivalent influenza vaccine ... safe and well tolerated and induced humoral immune responses, ...
(Date:6/29/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Russell 1000 Index, effective June 26, 2015. The Russell ... of the U.S. equity universe. It is a subset ... of the largest securities based on a combination of ... "We are pleased to be added to this important ...
(Date:6/29/2015)... SAN JOSE, Calif. , June 29, 2015 ... its expert medical workstation lineup. The high-powered, multi-functional ... th generation Intel® Haswell Core ... processor. Both provide significant data processing and computing ... visual performance, making the unit well suited for ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
(Date:6/30/2015)... ... 2015 , ... Some may define success as the sum of small efforts ... State Athletic Trainers’ Association (NYSATA) and its members continue to be acknowledged and applauded ... a number of members also received honors at the national level. , ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... aspiring data scientists and analysts who are currently attending an accredited American educational ... of data has provided new insight into healthcare, the environment, political campaigns, and ...
(Date:6/30/2015)... ... June 30, 2015 , ... Curly Hair Solutions™ is ... largest beauty event in the US, featuring products from all over the world. For ... The Collection is a line of hair styling products focused entirely on meeting the ...
(Date:6/29/2015)... (PRWEB) , ... June 30, 2015 , ... Aespala Medspa ... team, board-certified plastic surgeon Dr. David Dreyfuss. , Dr. Dreyfuss received his medical ... Reese Hospital in Chicago, followed by a Plastic Surgery Fellowship at the University of ...
(Date:6/29/2015)... ... June 30, 2015 , ... ... released a new website intended for executives and administrators with hospitals, healthcare providers, ... and the final product is a result of comprehensive research and implementation of ...
Breaking Medicine News(10 mins):Health News:NYSATA and Members Recognized with National Awards 2Health News:NYSATA and Members Recognized with National Awards 3Health News:Izenda Offers Embedded BI and Analytics Scholarship 2Health News:Izenda Offers Embedded BI and Analytics Scholarship 3Health News:Curly Hair Solutions™ Showcases Entire Curl Keeper™ Collection at Cosmoprof Las Vegas July 12 - 14 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 3Health News:Career Step Launches New Website to Better Meet Needs of Partners, Clients and Others Searching for Corporate Training Solutions 2
... national, regional, and global estimates of preterm birth reveals that ... 1.1 million of those babies die shortly after birth, making ... age 5. The alarming statistics in the new ... Report on Preterm Birth, highlight the need for more research ...
... The University of Texas MD Anderson Cancer Center President Ronald ... Sciences (NAS) - one of the most prestigious accolades in ... engineering. DePinho is the first member of the MD ... The NAS is a private, nonprofit society of distinguished scholars ...
... LONDON, ON Over the past decade, there has ... benefits of fish oil capsules. According to Dr. Louise ... oil may also improve outcomes for kidney patients undergoing ... (AV) grafts, artificial vessels created to join an artery ...
... -- A combination of moderate exercise and mental stimulation through ... loss more than computer use or exercise alone, according to ... of Mayo Clinic Proceedings , included more than 920 ... completed questionnaires about their computer use and physical activity over ...
... Mozes HealthDay Reporter , TUESDAY, May 1 (HealthDay ... known as melanoma, nature appears to have dealt women a ... every measure, an analysis of four European studies found that ... following an early stage melanoma diagnosis. That gap, researchers say, ...
... With nearly one-third of American children being overweight or ... more effective treatments. In many weight management programs, the dropout ... in successful programs, the benefits are usually short term., Although ... of treatment, theories of the family and how it functions ...
Cached Medicine News:Health News:New report shows 15 million babies born too soon every year 2Health News:UT MD Anderson President Ronald DePinho elected to National Academy of Sciences 2Health News:Everyday fish oil capsule may provide kidney-related benefits 2Health News:Exercise Plus Computer Time May Boost Seniors' Brains 2Health News:Women More Likely to Survive Melanoma Than Men: Study 2Health News:Women More Likely to Survive Melanoma Than Men: Study 3Health News:Treating childhood obesity: A family affair 2
... curtains or parting strip shields ... frame to form a free-standing, ... cleanliness to Class 10/ISO 3. ... lights, and ionizers are configured ...
Inquire...
Inquire...
Inquire...
Medicine Products: